(Q36677212)

15 August 2017

1 reference

title

Ligand-based vascular targeting of disease (English)

1 reference

15 August 2017

3

Jörg Scheuermann

1 reference

15 August 2017

Dario Neri

4

0 references

Eveline Trachsel

series ordinal

2

object named as

Eveline Trachsel

1 reference

15 August 2017

Jascha-N Rybak

1

1 reference

15 August 2017

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

1

1 reference

15 August 2017

22-40

1 reference

Role of angiogenesis in tumor growth and metastasis

15 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Making antibodies by phage display technology

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Discovering high-affinity ligands for proteins: SAR by NMR

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

In situ assembly of enzyme inhibitors using extended tethering

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Encoded self-assembling chemical libraries

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

SpeedScreen: The "missing link" between genomics and lead discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Mechanisms of angiogenesis and arteriogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Angiogenesis in health and disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Ocular Neovascularization

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Angiogenesis and ophthalmic disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Cancer anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Drug targeting to specific vascular sites

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

The tumour microcirculation as a target in cancer therapy: a clearer perspective

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

The development of combretastatin A4 phosphate as a vascular targeting agent

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Ep-CAM in malignant liver tumours

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Frequent EpCam protein expression in human carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Molecular targeting of angiogenesis for imaging and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Lack of specificity of endoglin expression for tumor blood vessels.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Robo4 is a vascular-specific receptor that inhibits endothelial migration

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Isolation and characterization of the notch ligand delta4.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Expression of the Extra Domain B of Fibronectin, a Marker of Angiogenesis, in Head and Neck Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Glucose-induced serum- and glucocorticoid-regulated kinase activation in oncofetal fibronectin expression.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Comparison of human tenascin expression in normal, simian-virus-40-transformed and tumor-derived cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

VEGF and the quest for tumour angiogenesis factors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Angiogenesis, lymphangiogenesis, and melanoma metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells; mechanisms and physiological significance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Involvement of phosphatidylinositol 4,5-bisphosphate in phosphatidylserine exposure in platelets: use of a permeant phosphoinositide-binding peptide.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Immunologic detection of phosphatidylserine externalization during thrombin-induced platelet activation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Polymer conjugates: nanosized medicines for treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Exploiting the enhanced permeability and retention effect for tumor targeting

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Genes expressed in human tumor endothelium

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Genomic analysis of metastasis reveals an essential role for RhoC

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Serial analysis of gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Tumor endothelial markers: new targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Identification of the cellular receptor for anthrax toxin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

In silico cloning of novel endothelial-specific genes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Screening phage display libraries for organ-specific vascular immunotargeting in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Design and use of phage display libraries for the selection of antibodies and enzymes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Organ targeting in vivo using phage display peptide libraries

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

A tumor-homing peptide with a targeting specificity related to lymphatic vessels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Arming antibodies: prospects and challenges for immunoconjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Efficient tumor targeting by single-domain antibody fragments of camels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

The influence of polyvalency on the binding properties of antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Mammalian cell expression of dimeric small immune proteins (SIP).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

High-affinity binders selected from designed ankyrin repeat protein libraries

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Fragment-based lead discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Fragment-Based Drug Discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

High-throughput crystallography for lead discovery in drug design.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

High-throughput crystallography to enhance drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

NMR in drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Tethering: fragment-based drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Fragonomics: fragment-based drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Seeing within: molecular imaging of the cardiovascular system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Transmittance of nonionizing radiation in human tissues

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Molecular imaging of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Selective targeted delivery of TNFalpha to tumor blood vessels.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Quantitation of the Tumor-Targeting Properties of Antibody Fragments Conjugated to Cell-Permeating HIV-1 TAT Peptides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Immunotherapy of metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Interleukin-12 in anti-tumor immunity and immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Immunocytokines: amplification of anti-cancer immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

ED-B fibronectin as a target for antibody-based cancer treatments

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Photosensitizer-antibody conjugates for detection and therapy of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Overview of monoclonal antibodies in cancer therapy: present and promise

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Monoclonal antibody drug immunoconjugates for targeted treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Oncofetal fibronectin in diabetic retinopathy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

VEGF and imaging of vessels in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuyt

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600181

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600181

1 reference

15 August 2017

1 reference

PubMed ID

17154429